Bis(2,4-dioxy pyrimidinyl) di:one cpds

Bis(2,4-dioxy pyrimidinyl) di:one cpds

Uracil derivs. of formula (I) are new. (R=H or 1-4C alkyl). Pref. R1 is Me. (I) are pref. prepd. by reacting a cpd. with the formula X-COCO-X (X=halogen atom or 1-4C alkoxy gp.) with two or more times the mol quantity, pref. two times the mol quantity of a pyridine silylide of formula (II). (I) have...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MIKIO KUMAKURA, SEITARO KAJIYA, TATSURO YOKOYAMA, YUTAKA OKAZAKI, HIROSHI KAWAZURA, AKIRA AWYA, HIROSHI TOKUDA, ISAO SAKANO
Format: Patent
Sprache:eng ; ita
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Uracil derivs. of formula (I) are new. (R=H or 1-4C alkyl). Pref. R1 is Me. (I) are pref. prepd. by reacting a cpd. with the formula X-COCO-X (X=halogen atom or 1-4C alkoxy gp.) with two or more times the mol quantity, pref. two times the mol quantity of a pyridine silylide of formula (II). (I) have immunity control effects and are suitable for treating chronic rheumatism, viral complaints and cancer, and have low toxicity. The estimated LD50 value in 7 day oral administration to ddY male mice was 1000 mg/kg or more. The dosage per 1 kg body wt. per day is suitably 1-30 mg for rectal application, 1-10 mg for intravenous injection and 1-30 mg for intramuscular or subcutaneous injection.